Diabetes prevalence estimates in schizophrenia and risk factor assessment

Annals of Clinical Psychiatry

Volumn 23, Issue 2, 2011, Pages 117-124

  Argo, Tami ^a   Carnahan, Ryan ^b   Barnett, Mitchell ^c   Holman, Timothy L ^d   Perry, Paul J ^b,c  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c TOURO UNIVERSITY CALIFORNIA   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Antipsychotic; Diabetes; Prevalence; Risk factors; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUCOSE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG MONITORING; FAMILY HISTORY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; METABOLIC BALANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT; PATIENT ATTITUDE; POPULATION RISK; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SCHIZOPHRENIA; SCREENING; SEDENTARY LIFESTYLE; SMOKING HABIT; TREATMENT DURATION; WAIST HIP RATIO; WEIGHT GAIN; BODY MASS; CHEMICALLY INDUCED DISORDER; COMORBIDITY; CROSS-SECTIONAL STUDY; MIDDLE AGED;

ADULT; ANTIPSYCHOTIC AGENTS; BODY MASS INDEX; COMORBIDITY; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERLIPIDEMIAS; MALE; MIDDLE AGED; RISK FACTORS; SCHIZOPHRENIA; SEDENTARY LIFESTYLE; WAIST-HIP RATIO;

EID: 80052093967     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Hossain P, Kawar B, El Nahas M. Obesity and diabetes in the developing world - a growing challenge. N Engl J Med. 2007;356:213-215. (Pubitemid 46143224)
2. Adams PF, Marano MA. Current estimates from the National Health Interview Survey, 1994. Vital Health Stat. 1995;193:1-260.
3. Pleis JR, Lethbridge-Çejku M. Summary health statistics for U.S. adults: National Health Interview Survey, 2006. Vital Health Stat 10. 2007;235:1-153.
4. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care. 1993;16:642-652. (Pubitemid 23097217)
5. Cowie CC, Rust KF, Byrd-Holt DD, et al. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999-2002. Diabetes Care. 2006;29:1263-1268. (Pubitemid 44125920)
6. Dynes JB. Diabetes in schizophrenia and diabetes in nonpsychotic medical patients. Dis Nerv Syst. 1969;30:341-344.
7. McKee HA, D'Arcy PF, Wilson PJ. Diabetes and schizophrenia - a preliminary study. J Clin Hosp Pharm. 1986;11:297-299. (Pubitemid 16038947)
8. Mukherjee S, Decina P, Bocola V, et al. Diabetes mellitus in schizophrenic patients. Compr Psychiatry. 1996;37:68-73. (Pubitemid 26024880)
9. Dixon L, Weiden P, Delahanty J, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903-912.
10. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45-53. (Pubitemid 41587462)
11. Mukherjee S, Schnur DB, Reddy R. Family history of type 2 diabetes in schizophrenic patients. Lancet. 1989;1:495. (Pubitemid 19063553)
12. Holmberg SK, Kane C. Health and self-care practices of persons with schizophrenia. Psychiatr Serv. 1999;50:827-829. (Pubitemid 29258962)
13. Brown S, Birtwistle J, Roe L, et al. The unhealthy lifestyle of people with schizophrenia. Psychol Med. 1999;29:697-701. (Pubitemid 29261358)
14. Lund BC, Perry PJ, Brooks JM, et al. Clozapine use in patients with schizophrenia and the risk of diabetes. Arch Gen Psychiatry. 2001;58:1172-1176.
15. Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry. 2002;63:1135-1139. (Pubitemid 36084058)
16. Kornegay CJ, Vasilakis-Scaramozza C, Jick H. Incident diabetes associated with antipsychotic use in the United Kingdom general practice research database. J Clin Psychiatry. 2002;63:758-762.
17. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study. BMJ. 2002;325:243.
18. Sernyak MJ, Leslie DL, Alarcon RD, et al. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry. 2002;159:561-566. (Pubitemid 34274937)
19. Fuller MA, Shermock KM, Secic M, et al. Comparative study of the development of diabetes mellitus in patients taking risperidone and olanzapine. Pharmacotherapy. 2003;23:1037-1043. (Pubitemid 36904003)
20. Gianfrancecso F, White R, Wang RH, et al. Antipsychotic-induced type 2 diabetes: evidence from a large health plan database. J Clin Psychopharmacol. 2003;23:328-335. (Pubitemid 36951173)
21. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med. 2001;111:716-723. (Pubitemid 34017524)
22. Koller EA, Cross JT, Doraiswamy PM, et al. Risperidone-associated diabetes mellitus: a pharmaco-vigilance study. Pharmacotherapy. 2003;23:735-744. (Pubitemid 36629078)
23. Koller EA, Doraiswamy PM. Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002;22:841-852. (Pubitemid 34743435)
24. Koller EA, Weber J, Doraiswamy PM, et al. A survey of reports of quetiapine-associated hyperglycemia and diabetes mellitus. J Clin Psychiatry. 2004;65:857-863.
25. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry. 1999;156:1686-1696. (Pubitemid 29517559)
26. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19-32. (Pubitemid 41587460)
27. Hägg S, Lindblom Y, Mjörndal T, et al. High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia. Int Clin Psychopharmacol. 2006;21:93-98. (Pubitemid 43740316)
28. Meyer J, Loh C, Leckband SG, et al. Prevalence of the metabolic syndrome in veterans with schizophrenia. J Psychiatr Pract. 2006;12:5-10. (Pubitemid 44378042)
29. De Hert MA, van Winkel R, Van Eyck D, et al. Prevalence of the metabolic syndrome in patients with schizophrenia treated with antipsychotic medication. Schizophr Res. 2006;83:87-93.
30. Koro CE, Fedder DO, L'Italien GJ, et al. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry. 2002;59:1021-1026.
31. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry. 2003;64:598-604. (Pubitemid 36618291)
32. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry. 2003;160:290-296. (Pubitemid 41110454)
33. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209-1223. (Pubitemid 41345943)
34. Stroup TS, Lieberman JA, McEvoy JP, et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsy-chotic. Am J Psychiatry. 2006;163:611-622. (Pubitemid 44464570)
35. Mortensen PB, Juel K. Mortality and causes of death in first admitted schizophrenic patients. Br J Psychiatry. 1993;163:183-189. (Pubitemid 23233086)
36. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11-53. (Pubitemid 28312203)
37. Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risks of cardiovascular disease. Am Heart J. 2005;150:1115-1121. (Pubitemid 41773510)
38. American Diabetes Association. Position statement: screening for diabetes. Diabetes Care. 2002;25(suppl 1):S21-24.
39. Cohn TA, Sernyak MJ. Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry. 2006;51:492-501. (Pubitemid 44166337)
40. Rolka DB, Narayan KMV, Thomson TJ, et al. Performance of recommended screening tests for undiagnosed diabetes and dysglycemia. Diabetes Care. 2001;24:1899-1903. (Pubitemid 33716498)
41. World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. Geneva, Switzerland: Department of Non-Communicable Disease Surveillance, World Health Organization; 1999.
42. Thakore JH, Mann JN, Vlahos I, et al. Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia. Int J Obes Relat Metab Disord. 2002;26:137-141. (Pubitemid 34098681)
43. Ryan MC, Flanagan S, Kinsella U, et al. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004;74:1999-2008. (Pubitemid 38210353)
44. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes Care. 2008;31(suppl 1): S12-64.
45. Perry PJ, Argo TR, Carnahan RM, et al. The association of weight gain and olanzapine plasma concentrations. J Clin Psychopharmacol. 2005;25:1-5.
46. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical anti-psychotics: an analysis of 45 published cases. Ann Clin Psychiatry. 2002;14:59-64. (Pubitemid 34538833)
47. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry. 2007;68(suppl 1):20-27.